In 287 Japanese women with uterine leiomyomas and heavy menstrual bleeding, oral linzagolix was non-inferior to leuprorelin for PBAC score <10 at weeks 6–12 (89.9% vs 90.8%). Hot flush affected 53.8% on linzagolix; breakthrough bleeding 55.6% on leuprorelin.
RCTn = 287
Osuga et al. Linzagolix versus leuprorelin in Japanese women with uterine leiomyomas: a phase 3, randomized, active-controlled, non-inferiority trial